Age 0 3 0 3 B-age
> 4 5 4 5 O
/= 5 7 5 7 O
18 8 10 8 10 B-lower_bound
years 11 16 11 16 I-lower_bound

Current 0 7 17 24 O
serious 8 15 25 32 O
medical 16 23 33 40 O
condition 24 33 41 50 O
which 34 39 51 56 O
may 40 43 57 60 O
interfere 44 53 61 70 O
with 54 58 71 75 O
subject 59 66 76 83 O
's 66 68 83 85 O
ability 69 76 86 93 O
to 77 79 94 96 O
complete 80 88 97 105 O
the 89 92 106 109 O
study 93 98 110 115 O
, 98 99 115 116 O
or 100 102 117 119 O
for 103 106 120 123 O
which 107 112 124 129 O
pulsed 113 119 130 136 O
ACTH 120 124 137 141 B-treatment
therapy 125 132 142 149 I-treatment
is 133 135 150 152 O
contraindicated 136 151 153 168 O
or 152 154 169 171 O
might 155 160 172 177 O
complicate 161 171 178 188 O
current 172 179 189 196 O
therapy 180 187 197 204 O
( 188 189 205 206 O
e.g. 189 193 206 210 O
, 193 194 210 211 O
cancer 195 201 212 218 B-cancer
, 201 202 218 219 O
severe 203 209 220 226 B-chronic_disease
psychiatric 210 221 227 238 I-chronic_disease
illness 222 229 239 246 I-chronic_disease
, 229 230 246 247 O
chronic 231 238 248 255 B-chronic_disease
infections 239 249 256 266 I-chronic_disease
, 249 250 266 267 O
autoimmune 251 261 268 278 B-chronic_disease
disorders 262 271 279 288 I-chronic_disease
) 271 272 288 289 O

Diabetes 0 8 290 298 B-chronic_disease
mellitus 9 17 299 307 I-chronic_disease
, 17 18 307 308 O
defined 19 26 309 316 O
as 27 29 317 319 O
pre 30 33 320 323 O
- 33 34 323 324 O
existing 34 42 324 332 O
diagnosis 43 52 333 342 O
, 52 53 342 343 O
fasting 54 61 344 351 B-clinical_variable
blood 62 67 352 357 I-clinical_variable
glucose 68 75 358 365 I-clinical_variable
> 76 77 366 367 O
125 78 81 368 371 B-lower_bound
mg 82 84 372 374 I-lower_bound
/ 84 85 374 375 I-lower_bound
dl 85 87 375 377 I-lower_bound
, 87 88 377 378 O
or 89 91 379 381 O
glycosylated 92 104 382 394 B-clinical_variable
hemoglobin 105 115 395 405 I-clinical_variable
> 116 117 406 407 O
/= 117 119 407 409 O
6.5 120 123 410 413 B-lower_bound
% 123 124 413 414 I-lower_bound

EDSS 0 4 415 419 B-clinical_variable
2.0 5 8 420 423 B-lower_bound
- 9 10 424 425 O
6.0 11 14 426 429 B-upper_bound

Known 0 5 430 435 O
intolerance 6 17 436 447 O
of 18 20 448 450 O
ACTH 21 25 451 455 B-treatment
or 26 28 456 458 O
corticosteroids 29 44 459 474 B-treatment

Male 0 4 475 479 B-gender
or 5 7 480 482 O
female 8 14 483 489 B-gender
patients 15 23 490 498 I-gender
with 24 28 499 503 O
a 29 30 504 505 O
confirmed 31 40 506 515 O
diagnosis 41 50 516 525 O
of 51 53 526 528 O
MS 54 56 529 531 B-chronic_disease
by 57 59 532 534 O
McDonald 60 68 535 543 O
criteria 69 77 544 552 O

Osteoporosis 0 12 553 565 B-chronic_disease
, 12 13 565 566 O
defined 14 21 567 574 O
as 22 24 575 577 O
pre 25 28 578 581 O
- 28 29 581 582 O
existing 29 37 582 590 O
diagnosis 38 47 591 600 O
or 48 50 601 603 O
T 51 52 604 605 B-clinical_variable
- 52 53 605 606 I-clinical_variable
score 53 58 606 611 I-clinical_variable
on 59 61 612 614 O
dual 62 66 615 619 B-treatment
- 66 67 619 620 I-treatment
energy 67 73 620 626 I-treatment
x 74 75 627 628 I-treatment
- 75 76 628 629 I-treatment
ray 76 79 629 632 I-treatment
absorptiometry 80 94 633 647 I-treatment
( 95 96 648 649 I-treatment
DEXA 96 100 649 653 I-treatment
) 100 101 653 654 I-treatment
scan 102 106 655 659 I-treatment
of 107 109 660 662 O
< 110 111 663 664 O
/= 111 113 664 666 O
-2.5 114 118 667 671 O

SPMS 0 4 672 676 B-chronic_disease
, 4 5 676 677 O
PPMS 6 10 678 682 B-chronic_disease
, 10 11 682 683 O
or 12 14 684 686 O
PRMS 15 19 687 691 B-chronic_disease
phenotype 20 29 692 701 O
, 29 30 701 702 O
according 31 40 703 712 O
to 41 43 713 715 O
Lublin 44 50 716 722 O
and 51 54 723 726 O
Reingold 55 63 727 735 O
criteria 64 72 736 744 O

Stimulant 0 9 745 754 B-treatment
medications 10 21 755 766 I-treatment
for 22 25 767 770 O
fatigue 26 33 771 778 O
( 34 35 779 780 O
such 35 39 780 784 O
as 40 42 785 787 O
methylphenidate 43 58 788 803 B-treatment
, 58 59 803 804 O
modafinil 60 69 805 814 B-treatment
, 69 70 814 815 O
armodafinil 71 82 816 827 B-treatment
, 82 83 827 828 O
amantadine 84 94 829 839 B-treatment
or 95 97 840 842 O
dextroamphetamine 98 115 843 860 B-treatment
) 115 116 860 861 O
will 117 121 862 866 O
be 122 124 867 869 O
permitted 125 134 870 879 O
, 134 135 879 880 O
but 136 139 881 884 O
subjects 140 148 885 893 O
will 149 153 894 898 O
be 154 156 899 901 O
asked 157 162 902 907 O
to 163 165 908 910 O
not 166 169 911 914 O
take 170 174 915 919 O
these 175 180 920 925 O
medications 181 192 926 937 O
on 193 195 938 940 O
study 196 201 941 946 O
visit 202 207 947 952 O
days 208 212 953 957 O
until 213 218 958 963 O
all 219 222 964 967 O
study 223 228 968 973 O
procedures 229 239 974 984 O
/ 239 240 984 985 O
assessments 240 251 985 996 O
are 252 255 997 1000 O
completed 256 265 1001 1010 O

Treatment 0 9 1011 1020 B-treatment
with 10 14 1021 1025 I-treatment
FDA 15 18 1026 1029 I-treatment
- 18 19 1029 1030 I-treatment
approved 19 27 1030 1038 I-treatment
first 28 33 1039 1044 I-treatment
- 33 34 1044 1045 I-treatment
line 34 38 1045 1049 I-treatment
MS 39 41 1050 1052 I-treatment
disease 42 49 1053 1060 I-treatment
- 49 50 1060 1061 I-treatment
modifying 50 59 1061 1070 I-treatment
therapies 60 69 1071 1080 I-treatment
( 70 71 1081 1082 O
B 71 72 1082 1083 B-treatment
- 72 73 1083 1084 I-treatment
interferon 73 83 1084 1094 I-treatment
, 83 84 1094 1095 O
glatiramer 85 95 1096 1106 B-treatment
acetate 96 103 1107 1114 I-treatment
, 103 104 1114 1115 O
fingolimod 105 115 1116 1126 B-treatment
, 115 116 1126 1127 O
teriflunomide 117 130 1128 1141 B-treatment
or 131 133 1142 1144 O
dimethyl 134 142 1145 1153 B-treatment
fumarate 143 151 1154 1162 I-treatment
) 151 152 1162 1163 O
will 153 157 1164 1168 O
be 158 160 1169 1171 O
permitted 161 170 1172 1181 O
, 170 171 1181 1182 O
as 172 174 1183 1185 O
long 175 179 1186 1190 O
as 180 182 1191 1193 O
treatment 183 192 1194 1203 B-treatment
has 193 196 1204 1207 O
been 197 201 1208 1212 O
ongoing 202 209 1213 1220 O
and 210 213 1221 1224 O
stable 214 220 1225 1231 O
for 221 224 1232 1235 O
at 225 227 1236 1238 O
least 228 233 1239 1244 O
3 234 235 1245 1246 B-lower_bound
months 236 242 1247 1253 I-lower_bound
prior 243 248 1254 1259 I-lower_bound
to 249 251 1260 1262 O
randomization 252 265 1263 1276 O

Treatment 0 9 1277 1286 B-treatment
with 10 14 1287 1291 I-treatment
cytotoxic 15 24 1292 1301 I-treatment
agents 25 31 1302 1308 I-treatment
( 32 33 1309 1310 O
including 33 42 1310 1319 O
but 43 46 1320 1323 O
not 47 50 1324 1327 O
necessarily 51 62 1328 1339 O
limited 63 70 1340 1347 O
to 71 73 1348 1350 O
mitoxantrone 74 86 1351 1363 B-treatment
, 86 87 1363 1364 O
cyclophosphamide 88 104 1365 1381 B-treatment
, 104 105 1381 1382 O
alemtuzumab 106 117 1383 1394 B-treatment
, 117 118 1394 1395 O
or 119 121 1396 1398 O
rituximab 122 131 1399 1408 B-treatment
) 131 132 1408 1409 O
within 133 139 1410 1416 O
3 140 141 1417 1418 B-upper_bound
years 142 147 1419 1424 I-upper_bound
prior 148 153 1425 1430 I-upper_bound
to 154 156 1431 1433 O
randomization 157 170 1434 1447 O

Treatment 0 9 1448 1457 B-treatment
with 10 14 1458 1462 O
dalfampridine 15 28 1463 1476 B-treatment
or 29 31 1477 1479 O
compounded 32 42 1480 1490 O
4 43 44 1491 1492 B-treatment
- 44 45 1492 1493 I-treatment
aminopyridine 45 58 1493 1506 I-treatment
( 59 60 1507 1508 I-treatment
4 60 61 1508 1509 I-treatment
- 61 62 1509 1510 I-treatment
AP 62 64 1510 1512 I-treatment
) 64 65 1512 1513 I-treatment
will 66 70 1514 1518 O
be 71 73 1519 1521 O
permitted 74 83 1522 1531 O
as 84 86 1532 1534 O
long 87 91 1535 1539 O
as 92 94 1540 1542 O
treatment 95 104 1543 1552 B-treatment
has 105 108 1553 1556 O
been 109 113 1557 1561 O
ongoing 114 121 1562 1569 O
and 122 125 1570 1573 O
stable 126 132 1574 1580 O
for 133 136 1581 1584 O
at 137 139 1585 1587 O
least 140 145 1588 1593 O
3 146 147 1594 1595 B-lower_bound
months 148 154 1596 1602 I-lower_bound
prior 155 160 1603 1608 I-lower_bound
to 161 163 1609 1611 O
randomization 164 177 1612 1625 O

Treatment 0 9 1626 1635 B-treatment
with 10 14 1636 1640 I-treatment
non 15 18 1641 1644 I-treatment
- 18 19 1644 1645 I-treatment
cytotoxic 19 28 1645 1654 I-treatment
immunosuppressive 29 46 1655 1672 I-treatment
agents 47 53 1673 1679 I-treatment
( 54 55 1680 1681 O
including 55 64 1681 1690 O
but 65 68 1691 1694 O
not 69 72 1695 1698 O
necessarily 73 84 1699 1710 O
limited 85 92 1711 1718 O
to 93 95 1719 1721 O
corticosteroids 96 111 1722 1737 B-treatment
, 111 112 1737 1738 O
ACTH 113 117 1739 1743 B-treatment
, 117 118 1743 1744 O
azathioprine 119 131 1745 1757 B-treatment
, 131 132 1757 1758 O
mycophenolate 133 146 1759 1772 B-treatment
mofetil 147 154 1773 1780 I-treatment
, 154 155 1780 1781 O
methotrexate 156 168 1782 1794 B-treatment
or 169 171 1795 1797 O
natalizumab 172 183 1798 1809 B-treatment
) 183 184 1809 1810 O
within 185 191 1811 1817 O
3 192 193 1818 1819 B-upper_bound
months 194 200 1820 1826 I-upper_bound
prior 201 206 1827 1832 I-upper_bound
to 207 209 1833 1835 O
randomization 210 223 1836 1849 B-treatment

